Creative Planning Grows Holdings in ICU Medical, Inc. $ICUI

Creative Planning grew its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 11.6% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 6,416 shares of the medical instruments supplier’s stock after buying an additional 667 shares during the quarter. Creative Planning’s holdings in ICU Medical were worth $848,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Cullen Frost Bankers Inc. bought a new position in ICU Medical in the second quarter valued at $38,000. Blue Trust Inc. increased its position in shares of ICU Medical by 17.6% during the 2nd quarter. Blue Trust Inc. now owns 942 shares of the medical instruments supplier’s stock valued at $124,000 after purchasing an additional 141 shares during the last quarter. AlphaQuest LLC raised its holdings in shares of ICU Medical by 3,058.3% during the 2nd quarter. AlphaQuest LLC now owns 1,516 shares of the medical instruments supplier’s stock valued at $200,000 after buying an additional 1,468 shares in the last quarter. United Services Automobile Association bought a new stake in ICU Medical in the 1st quarter worth approximately $218,000. Finally, Johnson Investment Counsel Inc. boosted its stake in ICU Medical by 17.7% in the second quarter. Johnson Investment Counsel Inc. now owns 1,699 shares of the medical instruments supplier’s stock worth $225,000 after buying an additional 256 shares in the last quarter. 96.10% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, VP Virginia Ruth Sanzone sold 930 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $142.34, for a total transaction of $132,376.20. Following the transaction, the vice president directly owned 5,456 shares of the company’s stock, valued at approximately $776,607.04. The trade was a 14.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Elisha W. Finney sold 1,285 shares of the firm’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $140.42, for a total value of $180,439.70. Following the completion of the sale, the director directly owned 3,995 shares of the company’s stock, valued at $560,977.90. The trade was a 24.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.50% of the stock is currently owned by company insiders.

ICU Medical Trading Down 1.5%

Shares of ICUI opened at $146.22 on Tuesday. The stock has a market capitalization of $3.61 billion, a P/E ratio of -96.20 and a beta of 0.83. ICU Medical, Inc. has a twelve month low of $107.00 and a twelve month high of $175.51. The company has a quick ratio of 1.17, a current ratio of 2.44 and a debt-to-equity ratio of 0.63. The firm has a fifty day simple moving average of $127.80 and a two-hundred day simple moving average of $128.57.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $2.03 EPS for the quarter, beating the consensus estimate of $1.43 by $0.60. The firm had revenue of $533.30 million during the quarter, compared to the consensus estimate of $511.46 million. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The company’s quarterly revenue was down 8.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.59 earnings per share. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. On average, research analysts anticipate that ICU Medical, Inc. will post 4.11 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on ICUI. Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a research note on Wednesday, October 8th. Raymond James Financial decreased their target price on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a research report on Friday, August 8th. KeyCorp boosted their price target on shares of ICU Medical from $173.00 to $175.00 and gave the stock an “overweight” rating in a research note on Friday, November 7th. Wall Street Zen lowered shares of ICU Medical from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, Piper Sandler lifted their price objective on ICU Medical from $153.00 to $172.00 and gave the stock an “overweight” rating in a report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $181.75.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.